Similar articles

• [Pharmaceutical characteristics of depot neuroleptics. Their use and efficacy in the psychiatric clinic].

  Mungiu OC, Chiriţă V, Boişteanu P, Mungiu A, Cosmovici N, Pirozynski T. Mungiu OC, et al. Rev Med Chir Soc Med Nat Iasi. 1988 Jan-Mar;92(1):43-7. Rev Med Chir Soc Med Nat Iasi. 1988. PMID: 2899341 Review. Romanian. No abstract available.
• High-dose treatment with neuroleptics in the acute phase of mental disease.

  Dencker SJ. Dencker SJ. Proc R Soc Med. 1976;69 suppl 1(Suppl 1):32-4. doi: 10.1177/00359157760690S108. Proc R Soc Med. 1976. PMID: 14332 Free PMC article.
• [Results of a survey on the use of delayed-action neuroleptics in psychiatry].

  Bourin M, Venisse JL, Lecuyer F. Bourin M, et al. Encephale. 1990 Sep-Oct;16(5):363-9. Encephale. 1990. PMID: 1979942 French.
• The risk/benefit ratio of depot neuroleptics: a Scandinavian perspective.

  Dencker SJ. Dencker SJ. J Clin Psychiatry. 1984 May;45(5 Pt 2):22-7. J Clin Psychiatry. 1984. PMID: 6143744
• Depot antipsychotic drugs and prevention of psychotic relapse.

  Barnes TR. Barnes TR. Clin Neuropharmacol. 1991;14 Suppl 2:S1-6. Clin Neuropharmacol. 1991. PMID: 1684307 Review. No abstract available.